Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by somweyungguyon Nov 15, 2016 2:32pm
170 Views
Post# 25464294

"give them some ?'able numbers and let them do the math"

"give them some ?'able numbers and let them do the math"My old buddy See-less always told me this ; - )

I noticed in the most recent MD&A, that the discussion around the 2nd interim result ( the important one with 55M+ shares printed, mostly at 29 CENTS ), that the number of patients the DSMB/FDA guided for patient count adjustment was NOT included.  This number is rather important, as per the Cormark report of Nov.6/16 that tells us the adjustment to 605 patients indicates an 11 to 12% absolute benefit or near double the advertised "per pre specificied protocol patient population"  Shouldn't this number be in the MD&A?  I would say YES, given the SAGA that insued round the 3 NR attmept to explain the interim results and the rather large ( 25% DILUTION to insiders )

I'm sick and tired of being "had" by intentional games and missing information.  Looks like some people think they can come to Canada and throw the Fiduciary Duty responsibility straight into the garbage binn.

I would say that had we been told that 11 to 12% binn achieved earlier on ( outside the "per specified pre protocol patient population" ) , the 5% surprise would have binn tough to "move the Coleman tent trailer" to the brink of the cliff...speaking of cliff, I wonder how much he is buying here?

Squire
Bullboard Posts